While there are no HAE treatments that are FDA-approved for use during pregnancy, the 2020 US HAEA guidelines recommend C1-INH for attack treatment in women who are pregnant or breastfeeding, a recommendation based on case reports and observational study data; prophylaxis is recommended for pregnant women before medical procedures, such as amniocentesis, chorionic villus sampling, and also before planned cesarean delivery and deliveries requiring vacuum or forceps. The gene discussed is SERPING1; the disease is hereditary angioedema.